Therefore, GSDME is responsible for reshaping the cisplatin-induced SCLC TME through the IL12RB1-IL12-CD4 effector memory T cell axis, thus improving the efficacy of chemo-immunotherapy (Figure 7). Here, CD4 is linked to small cell lung carcinoma.